These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 16105641)
1. What is the in vivo mechanism of action of levosimendan? MacGowan GA J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641 [No Abstract] [Full Text] [Related]
10. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites. Asif M Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341 [TBL] [Abstract][Full Text] [Related]
11. [Calcium sensitizers--a new group of drugs that increase myocardium contractility]. Laine M; Lehtonen L; Nieminen MS Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622 [No Abstract] [Full Text] [Related]
12. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency]. Schwinger RH; Brixius K Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725 [No Abstract] [Full Text] [Related]
13. Medical support and surgery of the failing heart: levosimendan. Toller W; Knez I Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353 [No Abstract] [Full Text] [Related]
15. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132 [TBL] [Abstract][Full Text] [Related]
17. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? Endoh M Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657 [TBL] [Abstract][Full Text] [Related]
18. Levosimendan in cardiogenic shock: the magic drug for every patient? Smetana P; Geppert A Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208 [No Abstract] [Full Text] [Related]
19. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713 [TBL] [Abstract][Full Text] [Related]
20. Evidence-based use of levosimendan in different clinical settings. De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]